Baupost Group raises stake in Idenix Pharmaceuticals

Baupost Group, the largest hedge fund firm in Boston, has bought up more than one-quarter of the stock of a Cambridge biotech firm working on drugs to treat hepatitis C. The hedge fund firm run by Seth Klarman now owns 27.6 percent of Idenix Pharmaceuticals Inc., according to a Nov. 1 filing with securities regulators, up from 18.5 percent in ... (more)

http://www.bostonglobe.com/business/2013/11/05/seth-klarman-baupost-group-becomes-largest-investor-idenix-hepatitis-drug-developer/QMsF5PMaKq07Dxrw9xDH9O/story.html